GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Burzynski Research Institute Inc (OTCPK:BZYR) » Definitions » Earnings per Share (Diluted)

BZYR (Burzynski Research Institute) Earnings per Share (Diluted) : $-0.01 (TTM As of Nov. 2024)


View and export this data going back to . Start your Free Trial

What is Burzynski Research Institute Earnings per Share (Diluted)?

Burzynski Research Institute's Earnings per Share (Diluted) for the three months ended in Nov. 2024 was $0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2024 was $-0.01.

Burzynski Research Institute's EPS (Basic) for the three months ended in Nov. 2024 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Nov. 2024 was $-0.01.

Burzynski Research Institute's EPS without NRI for the three months ended in Nov. 2024 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Nov. 2024 was $-0.01.

During the past 10 years, the average EPS without NRI Growth Rate was 9.00% per year.

During the past 13 years, Burzynski Research Institute's highest 3-Year average EPS without NRI Growth Rate was 30.70% per year. The lowest was -10.10% per year. And the median was 5.00% per year.


Burzynski Research Institute Earnings per Share (Diluted) Historical Data

The historical data trend for Burzynski Research Institute's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burzynski Research Institute Earnings per Share (Diluted) Chart

Burzynski Research Institute Annual Data
Trend Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

Burzynski Research Institute Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Burzynski Research Institute's Earnings per Share (Diluted)

For the Biotechnology subindustry, Burzynski Research Institute's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Burzynski Research Institute's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Burzynski Research Institute's PE Ratio distribution charts can be found below:

* The bar in red indicates where Burzynski Research Institute's PE Ratio falls into.



Burzynski Research Institute Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Burzynski Research Institute's Earnings Per Share (Diluted) for the fiscal year that ended in Feb. 2024 is calculated as

Diluted Earnings Per Share (A: Feb. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.335-0)/131.448
=-0.01

Burzynski Research Institute's Earnings Per Share (Diluted) for the quarter that ended in Nov. 2024 is calculated as

Diluted Earnings Per Share (Q: Nov. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.352-0)/131.448
=-0.00

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Burzynski Research Institute  (OTCPK:BZYR) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Burzynski Research Institute Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Burzynski Research Institute's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Burzynski Research Institute Business Description

Traded in Other Exchanges
N/A
Address
9432 Katy Freeway, Houston, TX, USA, 77055
Burzynski Research Institute Inc operates primarily as a research and development facility of Antineoplaston drugs currently being tested for the use in the treatment of cancer, and provides consulting services.
Executives
Monika Szopa-paszkowiak director 9432 KATY FWY #200, HOUSTON TX 77055
Frederick Richard Schiff director 9432 KATY FREEWAY, HOUSTON TX 77055
Barbara Burzynski director, 10 percent owner 9432 KATY FREEWAY, HOUSTON TX 77055
Carlton Hazlewood director 9432 KATY FREEWAY, HOUSTON TX 77055
Patryk Goscianski officer: Secretary and Treasurer 9432 KATY FREEWAY, HOUSTON TX 77055
Gregory Burzynski director 9432 KATY FREEWAY, HOUSTON TX 77055
Tomasz Janicki officer: VP of Clinical Trials 9432 KATY FREEWAY, HOUSTON TX 77055
Michael Driscoll director 9432 KATY FREEWAY, HOUSTON TX 77055
Stanislaw Burzynski director, 10 percent owner, officer: President 9432 KATY FREEWAY, HOUSTON TX 77055
Dudley Reece Anderson officer: Chief Financial Officer 9432 OLD KATY RD., SUITE 200, HOUSTON TX 77055

Burzynski Research Institute Headlines

No Headlines